The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply agreement for CASGEVY ® (exagamglogene ...

Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market hurdles. However, recent political developments, including both at the White House and the Food and Drug ...

CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom in November 2023, followed by the European Commission (EC) in February ...